anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study with a new, experimental drug is being done to assess safety and tolerability, and to explore effectiveness in the treatment of narcolepsy. Approximately 64 adult patients with narcolepsy with or without cataplexy will be recruited for the study. Patients who meet study criteria will need to stop taking their current narcolepsy and/ or other medication for at least 14 days before checking into the site for 3 nights. They will be randomly assigned to one of 4 treatment arms; each patient has an equal chance of receiving placebo, 10 mg JNJ-17216498, 50 mg JNJ-17216498 or 400 mg modafinil. Placebo has no active drug. Modafinil is a drug currently approved to treat narcolepsy. Patients will take the medication on only one day and will receive study medication in a blinded fashion, i.e. the patient, the doctor and the study sponsor will not know what group the patient is in until all patients complete the study. The investigator and the sponsor will monitor the study for the occurrence of possible side effects. In addition to a screening visit and the three nights at the site, there will be a follow-up visit 7-10 days after the day the study drug is taken. After the follow-up visit, patients may resume their previous narcolepsy medications. Medical history, physical examination, vision tests, blood pressure, heart rate, temperature, and ECGs will be checked periodically. Blood samples will be taken for standard safety laboratory tests as well as for the measurement of the drug blood level. The Maintenance of Wakefulness Test will be done to assess the patient's ability to resist falling asleep while reclining in a dark, quiet room; this will involve completing 7 sessions before dosing and 10 sessions after dosing. Patients will have two polysomnograms, a test of brain, muscle and eye activity during sleep, obtained by recording brain waves and other activities such as muscle and eye movement. Polysomnograms will be obtained overnight, once before and once after dosing. Patients will also complete brief questionnaires about their sleepiness and the status of their narcolepsy throughout the study. Patients will receive capsules containing either 10 mg JNJ-17216498, 50 mg JNJ-17216498, 400 mg modafinil and/or placebo on one day. Seven capsules will be taken orally in the morning and two capsules will be taken orally in the afternoon. Placebo contains no active drug. Modafinil is a drug currently approved to treat narcolepsy.
Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
Isradipine safety profile Isradipine, FDA approved for treatment of hypertension since 1990, has a well established data on its efficacy and safety in the hypertensive population (see package insert, Appendix 3). The side effect profile of isradipine is related to the primary mechanism of action of the agent as a vasodilator of the vascular smooth muscles and myocardium, and includes hypotension, bradycardia, weakness, and syncope. As per package insert, the most common adverse effects are headache (13.7% with active treatment versus 14% placebo), dizziness (7.3 vs 4.4) and peripheral edema as reflection of the vasodilatory effect which is dose dependent with incidence of about 3.5% at 5 mg, 8.7% at 10 mg and 8.5% at 20 mg. Of note the incidence of edema is substantially lower compared to CR preparation (9:13:36% for the respective doses). The other side effects include angina, asthenia, flushing, heart failure, and palpitations. According to the package insert, the adverse effects are usually not serious, dose dependent, and respond well to dose reduction or discontinuation of therapy. Isradipine has no effect on atrioventricular or sinoatrial conduction. The only absolute contraindications for isradipine are hypersensitivity to DHP compounds and hypotension defined as systolic blood pressure below 90 mm Hg. Until our studies, isradipine has not been tested in the PD population.
Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
A medical ink is loaded with a number of therapeutic agents. The ink is then applied directly to the tissue of a patient, either internally or externally, resulting in a therapeutic ink marking. The therapeutic ink marking can include surface activation of an immobilizing medication, controlled medication release, and/or the ability to use dyes or pigments to delineate different active ingredients by location and dosage. The active medicinal compounds can be placed on selective areas of the tissue as applied in the marking. The marking can provide a detectable and dosemetric controllable delivery to a specific targeted and localized location to provide the maximum therapeutic benefit. The medicated ink may be applied to a number of different methods. Dimensions of the markings can further serve to control and identify to the user the dosage amount of the medical agent applied to the tissue. Multiple types of medical agents with multiple application methods can be used. The medicated ink can be dyed, pigmented, or used as a colorless vehicle, and can be formulated to incorporate either immobilized or exuding active agents onto the tissue.
A nanoparticle complex for delivery to a cell, the nanoparticle complex comprising an RNA interfering agent and a delivery vehicle consisting of a liposome and a peptide. The peptide may be transmembrane, with at least a portion of the peptide being located outside of the liposome. The delivery vehicle is used to deliver the RNA interfering agent to the cell. RNA interference agents can target the activity of E3 ubiquitin ligase Itch. The complexes may be used to treat chemotherapy-resistant tumors and/or cancers. Also relates to compositions, combinations, kits, methods and uses thereof.
The oligonucleotide nanostructures enable pattern-recognized targeting of diseases, particularly useful as high-specificity detectors and inhibitors of viruses and toxins, such as for Dengue virus particles. The nanostructures include an oligonucleotide scaffold with a plurality of binders arranged in a pattern conforming to a plurality of surface epitopes of a target disease. Binding of the scaffolds to these surface epitopes has been shown to have inhibitory effects against the target disease. The scaffolds can also include functional domains that activate upon target binding. Assembly of the scaffolds can be achieved via annealing of separate oligonucleotide segments of predetermined length and sequence, which also advantageously define locations of binding domains in the resulting structure. This approach provides precise control over the spacing and orientation of epitope binding sites in the scaffold.
The intervention arm will consist of six KPSC service areas randomly assigned to the intervention arm. Immediately after primary HPV screening opens at KPSC, the intervention arm will receive the local tailoring interventions. All providers (physicians, nurses and medical assistants) and department administrator from the primary care departments (family medicine and internal medicine) and the department of obstetrics and gynecology at these six service areas randomized to this arm will be included in the study, as well as female patients at these service areas between age 30-65 who received cervical cancer screening during the data collection period.
FIELD: pharmaceutical industry and technology. SUBSTANCE: method involves mixing soluble salt of iron (III) with carbohydrates, the following partial neutralization of obtained mixture before onset of formation of iron (III) hydroxide deposit, alkalinization with alkali at stirring and heating, repeated neutralization of solution, its filtration and isolation of iron-containing complex by ultrafiltration on membranes with limit exclusion value 10 kDa or above. Carbohydrates taken among group comprising partially depolymerized dextrans with molecular mass from 1000 to 10000 Da, modified dextrans and dextrin are used as carbohydrates. Partial neutralization is carried out to pH value 1.8- 4.0 with concentrated solution of Na 2 CO 3  and/or NaOH and/or NaHCO 3 . Alkalinization of solution with alkali is carried out to pH value 10.5-11.5 with concentrated solution of NaOH at heating to 90-105 C for 1.0-2.5 h. Repeated neutralization of solution is carried out to pH value 5.9-6.5. Invention allows to obtain preparations of high quality used for treatment of patients with sideropenic anemia no causing by-side effects and stable in prolonged storage. EFFECT: improved method of preparing, improved properties. 9 cl, 2 ex
Participants received the study drug at dose level A in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
PURPOSE: A composition containing GEY, GYG, and GE peptides is provided to reduce blood glucose and to prevent and treat diabetes. CONSTITUTION: A food composition for reducing blood glucose contains peptides of Gly-Glu, Gly-Tyr-Gly, or Gly-Glu-Tyr as an active ingredient. The Gly-Glu, Gly-Tyr-Gly, or Gly-Glu-Tyr is isolated from organic materials or synthesized. The organic material is silkworm or egg. A pharmaceutical composition for preventing or treating diabetes contains the peptides as an active ingredient. The pharmaceutical composition is manufactured in the form of tablet, hard or soft capsule, liquid, or suspension.
Aim 1 will establish a testable AR-based smartphone app that measures clinically relevant lower-extremity motion components. Existing AR code will be adapted to identify and quantify hip, knee, and ankle range of motion in both the coronal and sagittal planes. Output will be produced directly to the phone display and can also be downloadable. Both single-motion and sequential-motion (gait) measures will be captured.

Aim 2 will then compare the app-based MCA to traditional gold standard MCA in healthy volunteers. A dedicated human biomechanics lab with capability for MCA with reflective markers will be utilized to test both MCA methods. Patients will perform a box jump and normal walking gait, and the measurements from both the standard marker-based MCA system and the smartphone markerless MCA system will be statistically compared.
BACKGROUND & AIMS: Hypercholesterolemia is frequently diagnosed in patients with primary biliary cholangitis (PBC). However, its association with the prognosis and lipid metabolism is unknown. In this study, we aimed to investigate the prognostic value of baseline total cholesterol (TC) levels in PBC and characterized the associated lipid metabolism.
METHODS: Five hundred and thirty-one patients with PBC without prior cirrhosis-related complications were randomly divided into the derivation and validation cohorts at a ratio of 7:3. Complete clinical data were obtained and analyzed. The endpoints were defined as liver-related death, liver transplantation, and cirrhosis-related complications. Lipidomics was performed in 89 patients and 28 healthy controls.
RESULTS: Baseline TC was independently associated with poor liver-related outcomes, and adjusted C-statistics were 0.80 (95% confidence interval [CI]: 0.74-0.85) and 0.88 (95% CI: 0.78-0.91) in the derivation and validation cohorts, respectively. The predictive ability of TC for disease outcomes was stable over time and comparable with the Globe score. The 200 mg/dL cut-off optimally divided patients into low- and high-TC groups. A combination of TC and Globe score provided a more accurate stratification of patients into risk subgroups. Lipidomics indicated an up-regulation of lipid families in high-TC patients. Pathway analysis of 66 up-regulated lipids revealed the dysregulation of glycerophospholipid and sphingolipid metabolism in high-TC patients, which were associated with poor liver-related outcomes.
CONCLUSIONS: Our results indicate that patients with PBC having baseline TC levels above 200 mg/dL have unique lipidome characteristics and are at a higher risk of poor liver-related outcomes.
PURPOSE:An improve for serum lipid useful as a food, or a drug, having improved reducing effect on free cholesterol and LDL cholesterol by a synergistic action, containing a specific triterpene alcohol and an a highly unsaturated oil. CONSTITUTION:The titled composition containing a triterpene alcohol selected from cycloartanol, 24-methylcycloartanol, and 24-methyulenecycloartanol and a highly unsaturated oil containing >=3 double bonds in the molecule. Eicosapentaenoic acid, eicosatetraenoic acid, linolenic acid, squalene, etc., may be cited as the highly unsaturated oil. An animal or vegetable oil containing them can also be used. The titled composition reduces extremely free cholesterol and LDL cholesterol, raises HDL cholesterol ratio in the-blood, and has good improving action on serum lipid. It also has high safety.
Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy. In the rare case where a patient may not tolerate 500 mg three times a day, he may remain on the study taking only 500 mg twice a day.
The comparison Intervention (Caregiver Nutritional Training (NT-MCI/AD) was based on the United States Department of Health and Human Services (USDHHS) "2005 My Pyramid Dietary Guidelines for Americans over Age 50." We chose a nutrition-based comparison intervention because information about dietary practices is not likely to affect mental health outcomes. The NT intervention was matched to the PST-based intervention in terms of number and duration of sessions.
In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially.

The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70 kg adult). A maximum of 4 g should not be exceeded during a 24 hour period.

The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.

Patients with severe hepatic disease metabolize metronidazole slowly, with resultant accumulation of metronidazole and its metabolites in the plasma. Accordingly, for such patients, doses below those usually recommended should be administered cautiously. Close monitoring of plasma metronidazole levels2 and toxicity is recommended.

The dose of metronidazole tablets should not be specifically reduced in anuric patients since accumulated metabolites may be rapidly removed by dialysis.
A composition of oral administration for improving skin cosmetic is provided to improve collagen synthesis without side effect and prevent skin aging. A composition for improving skin cosmetic for oral administration comprises green tea of powder type as an active ingredient. The composition further comprises chlorophyll-a, vitamin composite or theanine. The green tea of powder type is contained in 10~80 weight% based on total weight of composition. The vitamin composite comprises vitamin C and E, and curcumin in the ratio of 8:1:1. The composition is used in the form of pill, beverage, tea bag, instant tea, granule, tablet or capsule.
Hallux valgus (HV) is a common foot deformity whose multifactorial and complex and associated with other foot deformities. It is a common 1st ray deformity characterized by excessive angulation, rotation, and lateral deviation of the great toe at the first metatarsophalangeal joint . There are many symptoms of HV include poor fitting shoes, plantar foot pain, and pain in the medial first MTP joint .The resultant deformity causes pain and discomfort, which decreases the physical function of the foot and has been identified as a risk factor for falls in older people . Systematic reviews estimated the prevalence of HV to be more frequent with Old age and is more prevalent in women . Several risk factors for HV have been identified HV is associates with wearing high-heeled or narrow shoes . Foot problems are prevalent in old aged and are thought to be associated with high heels and narrow shoes The relationship between HV and obesity is less clear. Some studies have found an association between HV and increasing body mass index whereas others have found no association. Most recently, it has been suggested that the association between HV and BMI differs between the genders, with a lower prevalence with increasing BMI in women but no association in men and in Upper Egypt the principle investigator aim to collect data through a cross sectional study to know the prevalence and calculate the percentage of each certain risk factor through AP Standing Foot and evaluate HV angles and determind who has HV and then calaculate the prevalence and determind associated Risk Factors , while collecting cases the principle investigator focus on Emergency Unit on people without Foot Trauma , no neurological deficit and from outpatient clinic
Patients receive nab-paclitaxel/bevacizumab-complex IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may receive paclitaxel if supply of nab-paclitaxel is exhausted.
Although empathy for pain plays an important role in positive interpersonal relationships and encourages engagement in prosocial behavior, it remains largely unknown whether empathy for pain could be effectively altered by psychophysiological techniques. This study aimed to investigate the impact of a single session of diaphragmatic breathing practice on empathy for pain and examine the potential mechanism involving interoceptive awareness. A total of 66 healthy participants were randomly assigned to the intervention group or the control group. The intervention group received a 15-minute diaphragmatic breathing (DB) practice with real-time biofeedback, while the control group was to gaze at a black screen at rest and not engaged in any other activities. Before and after the invention, all participants were instructed to evaluate the intensity and unpleasantness of empathy for pain while watching different pictures with pain or non-pain conditions. The Multidimensional Assessment of Interoceptive Awareness (MAIA) was then administered to measure interoceptive awareness. The results indicated a significant interaction between group and time with regard to empathy for pain and MAIA. The DB group showed a statistically significant decrease in both pain intensity and unpleasantness during the pain picture condition, as well as a noteworthy increase in MAIA scores. The control group did not demonstrate any substantial changes. More importantly, the regulation of attention, a dimension of MAIA, had a significant mediating effect on the impact of diaphragmatic breathing on reported unpleasantness. Diaphragmatic breathing could serve as a simple, convenient, and practical strategy to optimize human empathy for pain that warrants further investigation, which has important implications not only for individuals with impaired empathy for pain but also for the improvement of interoceptive awareness.
Microplastics (MPs), a brand-new class of worldwide environmental pollutant, have received a lot of attention. MPs are consumed by both humans and animals through water, food chain and other ways, which may cause potential health risks. However, the effects of MPs on embryonic development, especially placental function, and its related mechanisms still need to be further studied. We investigated the impact on fetal development and placental physiological function of pregnant mice by consecutive gavages of MPs at 0, 25, 50, 100 mg/kg body weight during gestational days (GDs 0-14). The results showed that continuous exposure to high concentrations of MP significantly reduced daily weight gain and impaired reproductive performance of pregnant mice. In addition, MPs could significantly induce oxidative stress and placental dysfunction in pregnant mice. On the other hand, MPs exposure significantly decreased placental barrier function and induced placental inflammation. Specifically, MPs treatment significantly reduced the expression of tight junction proteins in placentas, accompanied by inflammatory cell infiltration and increased mRNA levels of pro-inflammatory cytokines and chemokines in placentas. Finally, we found that MPs induced placental apoptosis and endoplasmic reticulum (ER) stress through the GRP78/IRE1α/JNK axis, leading to placental dysfunction and decreased reproductive performance in pregnant mice. We revealed for the first time that the effects of MPs on placental dysfunction in pregnant animals. Blocking the targets of MPs mediated ER stress will provide potential therapeutic ideas for the toxic effects of MPs on maternal pregnancy.
The use of one or more cpds. chosen from weak water-soluble monocarboxylic acids (I) with a pKa of 3.8-5.1 or their salts, esters, amides or anhydrides as active agents for the regeneration, support, promotion or reinforcement of the natural protective or barrier function of healthy or diseased skin is claimed. (I) is pref. chosen from aliphatic satd. or unsatd. monocarboxylic acids with 1-6 C which are opt. substd. by a phenyl gp. or an OH gp. and their salts, esters, amides or anhydrides. The (I) may be used in conjunction with other skin care agents and assistants such as coenzymes, taurocholic acid, lipid precursors, lipids, antioxidants, moisturisers, water-binding agents, thickeners, fillers, perfume, colourants, emulsifiers, vitamins, preservatives, water, salts, etc.
Major depressive disorder (MDD) and substance-use disorders (SUDs) often lead to premature aging, increasing vulnerability to cognitive decline and other forms of dementia. This study utilized advanced systems bioinformatics to identify aging "signatures" in MDD and SUDs and evaluated the potential for known lifespan-extending drugs to target and reverse these signatures. The results suggest that inhibiting the transcriptional activation of FOS gene family members holds promise in mitigating premature aging in MDD and SUDs. Conversely, antidepressant drugs activating the PI3K/Akt/mTOR pathway, a common mechanism in rapid-acting antidepressants, may accelerate aging in MDD patients, making them unsuitable for those with comorbid aging-related conditions like dementia and Alzheimer's disease. Additionally, this innovative approach identifies potential anti-aging interventions for MDD patients, such as Deferoxamine, Resveratrol, Estradiol valerate, and natural compounds like zinc acetate, genistein, and ascorbic acid, regardless of comorbid anxiety disorders. These findings illuminate the premature aging effects of MDD and SUDs and offer insights into treatment strategies for patients with comorbid aging-related conditions, including dementia and Alzheimer's disease.